Cleveland Biolabs Inc. (CBLI) and Incuron Announce Start of US Trial With CBL0137
8/7/2013 9:49:00 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BUFFALO, N.Y., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) and Incuron, LLC, a joint venture between the Company and Bioprocess Capital Ventures, today announced that a multi-center, Phase 1, single agent, dose escalation trial evaluating intravenous administration of CBL0137 in patients with metastatic or unresectable advanced solid cancers and lymphomas is open for enrollment and that treatment of the first patient has been initiated.
Help employers find you! Check out all the jobs and post your resume.
comments powered by